ArQule, Inc.
(NASDAQ : ARQL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -0.99%28.1214.1%$165.46m
AMRNAmarin Corp. Plc -3.31%19.551.7%$156.49m
AXSMAxsome Therapeutics, Inc. 0.62%85.731.9%$91.16m
BHCBausch Health Cos., Inc. -1.00%28.120.0%$83.76m
GWPHGW Pharmaceuticals Plc -1.76%112.496.2%$72.32m
PRGOPerrigo Co. Plc -0.31%58.586.8%$63.55m
JAZZJazz Pharmaceuticals Plc -0.85%144.502.3%$63.40m
SAVACassava Sciences, Inc. 1.05%7.250.0%$61.43m
ICPTIntercept Pharmaceuticals, Inc. -2.63%94.1116.9%$59.89m
SAGESAGE Therapeutics, Inc. -1.46%67.038.6%$57.76m
HZNPHorizon Therapeutics Plc -1.08%35.676.6%$55.80m
MNKMallinckrodt Plc -5.32%4.9020.9%$41.40m
ICLRICON plc -2.14%171.224.2%$38.71m
CTLTCatalent, Inc. 0.29%61.762.4%$38.07m
UTHRUnited Therapeutics Corp. 0.83%90.0714.3%$35.08m

Company Profile

ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.